Oleksii Kalachov

Oleksii Kalachov

Auto-generated profile, based on publicly available information

Oleksii Kalachov

Communal Non-Commercial Enterprise «Kyiv City Clinical Oncology Center

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2024 in Family medicine. European practices
Verified
Journal Article
Open access
PDF file
RMRaisa Moiseenko
Raisa Moiseenko
OKOleksii Kalachov
Oleksii Kalachov
PGProkip Gordiichuk
Prokip Gordiichuk
AKAndrii Kondratenko
Andrii Kondratenko
AKAnna Konysheva
Anna Konysheva
АСАнастасія Самусєва
Анастасія Самусєва
The city of Kyiv is characterized by a high level (258.6 cases per 100,000 population) of cancer incidence and mortality. The objective: to determine the problem and prospects of providing inpatient oncology care based on the experience of the department of the Kyiv City Clinical Oncology Center (KCCOC). Materials and methods. A retrospective analysis of the work of the palliative care department of communal non-commercial enterprise “KCCOC” for 2001–2023 was carried out. The center includes a 25-bed hospital and mobile palliative care teams. A multidisciplinary approach was the basis of providing palliative care to an incurable cancer patient. Results. During this period 9,164 cancer patients in the terminal stage with high mortality rate (81.04%) received inpatient care. The average duration of stay in the hospital was 17.7 bed-days. Approximately 6% of patients readmit to the department, some of them – 3-4 times. Approximately 94% of hospitalized patients had a pain syndrome, 86% of patients received opioid analgesia. During this period, mobile palliative care teams registered and served 3,124 cancer patients, among whom 62% of patients were transferred after inpatient treatment, more than 5,700 primary visits were made. The clinical route of the palliative patient was developed and improved, which made it possible to optimize palliative care for a seriously ill oncological patient. The peculiarities of providing palliative care to incurable oncological patients in the conditions of martial law have been determined. Conclusions. Comprehensive palliative care should be a unified system of mobile and stationary care, which will make possible to control the somatic condition of the palliative patient, correct the symptoms of the disease, provide long-term support to the patient at home, which is economically feasible, allows to provide care to a larger number of patients and hospitalize in time if it is necessary. The creation of an extensive system of mobile palliative care is promising in improvement of palliative care for oncology patients (it will reduce the burden on general somatic hospitals and inpatient palliative departments), as well as qualitatively improve the provision of palliative care to patients in the primary care network.

14 October 2025 in Likars'ka Sprava
Verified
Journal Article
Open access
ПГП. І. Гордійчук
П. І. Гордійчук
ДМД. В. Мельник
Д. В. Мельник
MГM. P. Гордійчук
M. P. Гордійчук
ОКО. В. Калачов
О. В. Калачов
Background. The management of chronic myeloid leukemia (CML) has been revolutionized by tyrosine kinase inhibitors (TKIs), shifting the therapeutic goal from survival to achieving treatment-free remission (TFR). However, TFR is undermined by molecular relapse in 40–60% of patients, highlighting the imprecision of the current “gold standard” monitor, quantitative reverse-transcription PCR (qPCR), at the deep molecular response (DMR) level. Objective. The review systematically evaluates the comparative analytical and clinical performance of digital PCR (dPCR) versus qPCR for monitoring minimal residual disease (MRD) in CML. Methods. According to PRISMA-ScR guidelines, a systematic search of PubMed, Scopus, and Embase (from 2021 to present) was conducted, supplemented by a review of major clinical guidelines (ELN, NCCN, ESMO) from the last decade. Studies were selected for comparing dPCR and qPCR in the context of BCR-ABL1 quantification, DMR, and TFR. Results. The evidence demonstrates that dPCR is an analytically superior technology, offering absolute quantification that is more accurate, precise, and tolerant to amplification inhibitors than qPCR, especially at the very low levels of disease relevant to TFR decisions. Recent clinical data, most notably the experimental non-pharmacologic trial “DEep MOlecular respoNSe and TRAnscript Type Evaluation by digital PCR – Studio DEMONSTRATE”, establishes dPCR as a prognostically superior tool, capable of anticipating the achievement of a “true” and stable DMR by a median of 5 months compared to qPCR (p = 0.0017). This finding suggests dPCR can more accurately stratify patients, potentially averting TFR attempts in those with residual disease undetectable by qPCR. A significant “standardization lag” exists, wherein laboratory guidelines (ELN 2023) validate dPCR, but major clinical guidelines (NCCN 2024) have not yet integrated it into their primary monitoring algorithms. Conclusions. dPCR represents a significant clinical advance in CML monitoring. Its superior prognostic power to define stable DMR makes it an essential tool for enhancing the safety and success of TFR. The primary barrier to its widespread clinical adoption is no longer a lack of evidence, but the urgent, logistical need for methodological standardization and its formal integration into international clinical practice guidelines.